Clyra Medical Technologies, a Subsidiary of BioLargo, Appoints Dr. Steven J. Kavros as Chief Medical Officer
BioLargo's subsidiary, Clyra Medical Technologies, has appointed Dr. Steven J. Kavros as its new Chief Medical Officer. Dr. Kavros brings extensive experience in advanced wound healing and limb preservation, having spent over 20 years at the Mayo Clinic. He has a strong background in research, medical education, and the medical device industry. Dr. Kavros has given over 1,800 presentations at conferences and authored numerous peer-reviewed papers. His expertise includes successfully bringing multiple products to market in wound healing, limb preservation, and orthopedics. Clyra CEO Steve Harrison believes Dr. Kavros' clinical expertise and business insight will be important for the company's manufacturing and distribution plans for its Bioclynse product.
La filiale di BioLargo, Clyra Medical Technologies, ha nominato il Dr. Steven J. Kavros nuovo Chief Medical Officer. Il Dr. Kavros porta con sé un'ampia esperienza nella cura avanzata delle ferite e nella preservazione degli arti, avendo trascorso oltre 20 anni presso la Mayo Clinic. Ha una solida formazione nella ricerca, nell'educazione medica e nell'industria dei dispositivi medici. Il Dr. Kavros ha tenuto oltre 1.800 presentazioni a conferenze e ha scritto numerosi articoli peer-reviewed. La sua esperienza include il successo nel portare sul mercato molteplici prodotti nel settore della cura delle ferite, preservazione degli arti e ortopedia. Il CEO di Clyra, Steve Harrison, crede che l'expertise clinica e la visione aziendale del Dr. Kavros saranno importanti per i piani di produzione e distribuzione dell'azienda per il suo prodotto Bioclynse.
La subsidiaria de BioLargo, Clyra Medical Technologies, ha nombrado al Dr. Steven J. Kavros como su nuevo Director Médico. El Dr. Kavros aporta una amplia experiencia en la curación avanzada de heridas y la preservación de extremidades, habiendo pasado más de 20 años en la Clínica Mayo. Tiene una sólida formación en investigación, educación médica y la industria de dispositivos médicos. El Dr. Kavros ha realizado más de 1,800 presentaciones en conferencias y ha escrito numerosos artículos revisados por pares. Su experiencia incluye haber llevado con éxito varios productos al mercado en curación de heridas, preservación de extremidades y ortopedia. El CEO de Clyra, Steve Harrison, cree que la experiencia clínica y la visión empresarial del Dr. Kavros serán importantes para los planes de fabricación y distribución de la empresa para su producto Bioclynse.
바이올라고의 자회사인 Clyra Medical Technologies는 스티븐 J. 카브로스 박사를 새로운 최고 의료 책임자로 임명했습니다. 카브로스 박사는 메이요 클리닉에서 20년 이상의 경력을 바탕으로 고급 상처 치유 및 사지 보존에 대한 폭넓은 경험을 가지고 있습니다. 그는 연구, 의학 교육 및 의료 기기 산업에서 강력한 배경을 가지고 있습니다. 카브로스 박사는 1,800회 이상의 컨퍼런스 발표를 했으며 수많은 동료 검토 논문을 저술했습니다. 그의 전문 분야에는 상처 치유, 사지 보존 및 정형외과에서 여러 제품을 성공적으로 시장에 출시한 경험이 포함됩니다. Clyra의 CEO 스티브 해리슨은 카브로스 박사의 임상 전문 지식과 비즈니스 통찰력이 Bioclynse 제품의 제조 및 유통 계획에 중요할 것이라고 믿고 있습니다.
La filiale de BioLargo, Clyra Medical Technologies, a nommé le Dr Steven J. Kavros nouveau directeur médical. Le Dr Kavros apporte une vaste expérience en matière de cicatrisation avancée des plaies et de préservation des membres, ayant passé plus de 20 ans à la Mayo Clinic. Il a un solide bagage en recherche, en éducation médicale et dans l'industrie des dispositifs médicaux. Le Dr Kavros a donné plus de 1 800 présentations lors de conférences et a rédigé de nombreux articles révisés par des pairs. Son expertise inclut le lancement réussi de plusieurs produits dans les domaines de la cicatrisation des plaies, de la préservation des membres et de l'orthopédie. Le PDG de Clyra, Steve Harrison, estime que l'expertise clinique et l'aperçu commercial du Dr Kavros seront importants pour les plans de fabrication et de distribution de l'entreprise concernant son produit Bioclynse.
Die Tochtergesellschaft von BioLargo, Clyra Medical Technologies, hat Dr. Steven J. Kavros zum neuen Chief Medical Officer ernannt. Dr. Kavros bringt umfangreiche Erfahrung in der fortschrittlichen Wundheilung und der Erhaltung von Gliedmaßen mit, nachdem er über 20 Jahre an der Mayo Clinic tätig war. Er hat einen starken Hintergrund in der Forschung, der medizinischen Ausbildung und der Medizintechnik. Dr. Kavros hat über 1.800 Präsentationen auf Konferenzen gehalten und zahlreiche von Fachkollegen begutachtete Artikel verfasst. Zu seiner Expertise gehört es, mehrere Produkte auf dem Markt für Wundheilung, Gliedmaßenerhaltung und Orthopädie erfolgreich einzuführen. Der CEO von Clyra, Steve Harrison, ist der Ansicht, dass die klinische Expertise und die Geschäftserkenntnisse von Dr. Kavros für die Produktions- und Vertriebspläne des Unternehmens für das Produkt Bioclynse wichtig sein werden.
- Appointment of highly experienced Chief Medical Officer with expertise in wound healing
- Dr. Kavros brings 20+ years of experience from prestigious Mayo Clinic
- New CMO has a track record of successfully bringing medical products to market
- Appointment aligns with Clyra's plans for manufacturing and distribution of Bioclynse product
- None.
WESTMINSTER, CA / ACCESSWIRE / September 9, 2024 / BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable environmental and life sciences technologies, announced that its partially owned subsidiary Clyra Medical Technologies had appointed Dr. Steven J. Kavros as its new Chief Medical Officer.
Dr. Kavros brings a wealth of medical expertise and experience in advanced wound healing and limb preservation to his new role at Clyra. He spent over 20 years at the prestigious Mayo Clinic in Rochester, MN, where he served as Director at the Gonda Vascular Wound Healing Center, and was involved in both research and patient care. He was also deeply engaged in medical education as Associate Professor at the Mayo Clinic's Alix School of Medicine.
Dr. Kavros is also an accomplished researcher and speaker, having given over 1,800 presentations related to his research activities at national and international conferences, and lead author of numerous peer-reviewed papers centered on new medical technologies and evidence-based medicine.
In addition to his clinical and academic achievements, Dr. Kavros has a proven track record in the medical device industry, successfully bringing to market multiple products in advanced wound healing, limb preservation, and orthopedics. He has also served in leadership roles at EPIEN Medical, TEI Biosciences, Miromatrix Medical, and Innovacyn.
Dr. Kavros earned a bachelor's degree in Biology with honors and a minor in Chemistry from Rutgers University and subsequently graduated from Temple University School of Podiatric Medicine with highest honors in surgery, orthopedics, biomechanics and podiatric medicine. Dr. Kavros is also a certified wound specialist through the American Board of Wound Management, a fellow of the American College of Certified Wound Specialists, and a founding member of the American Professional Wound Care Association, where he also served as scientific chair and later as its president from 2015-2019.
Clyra CEO Steve Harrison commented "Dr. Kavros' unique blend of clinical expertise and business insight will prove invaluable to support our significant investments for at-scale manufacturing and distribution of our Bioclynse product. His skills in leadership, team building, and entrepreneurship align perfectly with Clyra's vision and goals."
About Clyra Medical Technologies, Inc.
Clyra Medical Technologies, founded on our mission of "Make Lives Better", is a healthcare company that develops and commercializes products designed to safely treat wound and skin infections and promote wound healing, while reducing the need for antibiotics.
Clyra Medical Technologies is a proud member of the BioLargo Family of Companies (www.biolargo.com). Clyra is a subsidiary of BioLargo, Inc., a publicly traded company, with the stock symbol (OTCQX:BLGO) BioLargo is a technology innovator and solutions provider focused on some of the world's most pressing human health and environmental challenges including advanced water treatment, environmental remediation, air quality control, medical technologies, and more.
About BioLargo, Inc.
BioLargo, Inc. (OTCQX: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
dennis.calvert@biolargo.com
888-400-2863
SOURCE: BioLargo, Inc.
View the original press release on accesswire.com
FAQ
Who is the new Chief Medical Officer of Clyra Medical Technologies (BLGO)?
What is Dr. Steven J. Kavros' background before joining Clyra Medical Technologies (BLGO)?
How might Dr. Kavros' appointment impact Clyra Medical Technologies (BLGO)?
What specific expertise does Dr. Kavros bring to Clyra Medical Technologies (BLGO)?
